Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | CNR1 | P21554 | 3/20 | 0.46 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3917626 | 0.92 | LSS (0.46) | KDM4EALDH1A1CNR1TSHRPTGDR2 | |
| SCHEMBL4163738 | 0.89 | MEN1 (0.46) | ALDH1A1CNR1TSHRLMNAGAA | |
| SCHEMBL4144085 | 0.88 | PTGDR2 (0.42) | KDM4EALDH1A1CNR1TSHRPTGDR2 | |
| SCHEMBL3921517 | 0.88 | CNR1 (0.41) | KDM4EALDH1A1CNR1TSHRSMN1; SMN2 | |
| SCHEMBL3607836 | 0.87 | CNR1 (0.41) | ALDH1A1CNR1TSHRPTGDR2LMNA | |
| SCHEMBL3600846 | 0.87 | GAA (0.43) | ALDH1A1CNR1TSHRLMNAGAA | |
| SCHEMBL3594052 | 0.86 | CNR1 (0.40) | ALDH1A1CNR1TSHRPTGDR2LMNA | |
| SCHEMBL3913275 | 0.85 | PTPN11 (0.45) | ALDH1A1CNR1TSHRLMNAPOLB | |
| SCHEMBL3604717 | 0.84 | PTGDR2 (0.40) | CNR1PTGDR2LMNAGAA | |
| SCHEMBL3921481 | 0.84 | KDM4E (0.49) | KDM4EALDH1A1CNR1LMNAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090209552-A1 | Organic Compounds | NOVARTIS AG | 2009-08-20 | — | — | US | claimed |
| US-20090209552-A1 | Organic Compounds | NOVARTIS AG | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209552-A1 | Organic Compounds | SLCO1B3, SLCO1B1, SLC10A6 | KDM4E 1399/4885ALDH1A1 439/4885CNR1 657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.